Home » Drug Information » FDA Approved Drugs » 2001
Medical Areas: Ophthalmology | Family Medicine
View By:YearCompanyConditionsTherapeutic AreasDrug Names
Travatan (travoprost ophthalmic solution)
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Approval Status: Approved March 2001
Treatment Area: Glaucoma or ocular hypertension
Travatan has been approved by the FDA for the reduction of
elevated intraocular pressure (IOP) in patients with open-angle
glaucoma or ocular hypertension. It is indicated for patients who
are intolerant of or insufficiently responsive to other intraocular
pressure lowering medications.
Travoprost, the active ingredient in Travatan, is a synthetic
prostaglandin analogue. It targets the prostanoid receptor and is
believed to reduce intraocular pressure by increasing the drainage
of fluid (aqueous humor) from the eye.
There are approximately two to three million individuals in the
United States with glaucoma, a condition often associated with
elevated intraocular pressure leading to optic nerve damage.
Glaucoma is a leading cause of blindness, accounting for
approximately 12% of all new cases in the United States each year.
While glaucoma significantly affects all races and ages, it appears
to particularly target individuals of African descent, appearing at
an earlier age and progressing at a more rapid rate. Travatan,
unlike other glaucoma treatments, has demonstrated greater
effectiveness in African-American patients.
Trial results demonstrated that subjects with open-angle
glaucoma or ocular hypertension who were treated with Travatan
Ophthalmic Solution 0.004% experienced 7-8 mm Hg reductions in
intraocular pressure. Subjects had a baseline pressure of 25-27 mm
Hg and were dosed once-daily in the evening. Subgroup analyses of
these trials showed that mean IOP reduction in African-American
subjects was up to 1.8 mm Hg greater than in non-African-American
subjects. At this time, it is not known whether this difference is
due to race or to heavily pigmented irides.
A multicenter, randomized, controlled trial evaluated the
efficacy of Travatan dosed adjunctively to Timoptic. Results showed
that subjects with a mean baseline intraocular pressure of 24-26 mm
Hg on Timoptic 0.5% BID who were treated with Travatan 0.004% dosed
QD adjunctively to Timoptic 0.5% BID demonstrated 6-7 mm Hg
reductions in intraocular pressure.
The use of Travatan has been associated with possibly permanent
changes in pigmented tissues, including increased pigmentation of
the iris and periorbital tissue (eyelid) and increased pigmentation
and growth of eyelashes.
The most common eye-related adverse event reported in clinical
trials was ocular hyperemia, which was reported in 35 to 50% of
subjects. Other events included (but are not limited to) the
- Decreased visual acuity
- Eye discomfort
- Foreign body sensation
Mechanism of Action
Travoprost free acid is a selective FP prostanoid receptor
agonist which is believed to reduce intraocular pressure by
increasing uveoscleral outflow. The exact mechanism of action is
unknown at this time. (from Travatan Label)
Travatan should not be administered while wearing contact lenses
- the drug contains benzalkonium chloride, which may be absorbed by
the lens. Additionally, contact between the tip of the container
and the eye or surrounding area should be avoided when
administering Travatan. This contact could cause the tip to become
contaminated and result in ocular infection.
If you are interested in learning more about glaucoma, please
visit the National Institutes of Health, National Eye
Additional information on Travatan can be obtained by visiting